US Stock Market Move | BEIGENE (ONC.US) rises more than 3% in pre-market trading, Lenvima monoclonal antibody approved for new indication in the United States.
On Tuesday, BeiGene Ltd. (ONC.US) rose more than 3% in pre-market trading, reaching $253.98 in the US stock market.
On Tuesday, BEIGENE (ONC.US) saw its US stock price rise over 3% in pre-market trading to $253.98. On the news front, on March 4th, BEIGENE announced that the US FDA had approved the combination of tislelizumab (anti-PD-1 antibody) with platinum-based chemotherapy for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) in adult patients with PD-L1 expression (1).
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
